The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Analysis of outcomes of younger CLL patients
Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, outlines the results from a pooled analysis of the outcomes of younger (≤ 55 years) compared with older chronic lymphocytic leukemia (CLL) patients receiving first-line treatment in seven phase II or III clinical trials conducted by the German CLL Study Group (GCLLSG). Dr Eichhorst emphasizes that a lot of progress is needed to increase overall survival in younger CLL patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
